In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $4.70, marking a -3.29% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.01%.

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

While standard models suffer from context rot as data grows, MIT’s new Recursive Language Model (RLM) framework treats ...

Recursion plans to present updated data from the TUPELO trial in an upcoming webinar scheduled for December 8, 2025. This presentation will provide further insights into the drug’s safety and efficacy ...

Researchers at MIT's CSAIL published a design for Recursive Language Models (RLM), a technique for improving LLM performance on long-context tasks. RLMs use a programming environment to recursively ...

Java 26, due in March with structured concurrency, lazy constants, AOT object caching, and primitive types in patterns, instanceof, and switch, has entered a second rampdown phase for bug fixes. Java ...

CEO Chris Gibson highlighted significant progress in 2024, including clinical data readouts from REC-617 and REC-994, which showed early efficacy signals and robust safety, respectively. REC-617, a ...